- Home
- IOBT vs ACHV Comparison
IOBT vs ACHV Comparison
Compare IOBT & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- ACHV
- Stock Information
- Founded
- IOBT 2014
- ACHV N/A
- Country
- IOBT Denmark
- ACHV United States
- Employees
- IOBT N/A
- ACHV N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IOBT Health Care
- ACHV Health Care
- Exchange
- IOBT Nasdaq
- ACHV Nasdaq
- Market Cap
- IOBT 114.6M
- ACHV 131.3M
- IPO Year
- IOBT 2021
- ACHV N/A
- Fundamental
- Price
- IOBT $1.95
- ACHV $2.83
- Analyst Decision
- IOBT Strong Buy
- ACHV Strong Buy
- Analyst Count
- IOBT 3
- ACHV 2
- Target Price
- IOBT $8.67
- ACHV $16.00
- AVG Volume (30 Days)
- IOBT 8.9M
- ACHV 1.5M
- Earning Date
- IOBT 08-14-2025
- ACHV 11-06-2025
- Dividend Yield
- IOBT N/A
- ACHV N/A
- EPS Growth
- IOBT N/A
- ACHV N/A
- EPS
- IOBT N/A
- ACHV N/A
- Revenue
- IOBT N/A
- ACHV N/A
- Revenue This Year
- IOBT N/A
- ACHV N/A
- Revenue Next Year
- IOBT N/A
- ACHV N/A
- P/E Ratio
- IOBT N/A
- ACHV N/A
- Revenue Growth
- IOBT N/A
- ACHV N/A
- 52 Week Low
- IOBT $0.66
- ACHV $1.84
- 52 Week High
- IOBT $2.79
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- IOBT 56.62
- ACHV 50.85
- Support Level
- IOBT $1.53
- ACHV $2.91
- Resistance Level
- IOBT $1.77
- ACHV $3.14
- Average True Range (ATR)
- IOBT 0.21
- ACHV 0.26
- MACD
- IOBT 0.01
- ACHV -0.00
- Stochastic Oscillator
- IOBT 33.33
- ACHV 29.79
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.